Cipla’s arm acquires 75% stake in Mabpharm

17 Jul 2014 Evaluate

Cipla’s wholly owned subsidiary Meditab Specialities (MSPL) has acquired 75% stake in Mabpharm. The company was earlier holding 25% stake in Mabpharm. Consequent to the acquisition of the aforesaid stake, Mabpharm has now become 100% subsidiary of the company.

Mabpharm is inter alia engaged in development of monoclonal anitbodies for treatment of cancer and auto-immune diseases. While, Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.

Cipla Share Price

1494.40 -10.65 (-0.71%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×